SPRO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SPRO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Spero Therapeutics's shares outstanding for the quarter that ended in Sep. 2024 was 54.31 Mil.
Spero Therapeutics's quarterly shares outstanding increased from Jun. 2024 (54.01 Mil) to Sep. 2024 (54.31 Mil). It means Spero Therapeutics issued new shares from Jun. 2024 to Sep. 2024 .
Spero Therapeutics's annual shares outstanding increased from Dec. 2022 (52.46 Mil) to Dec. 2023 (53.00 Mil). It means Spero Therapeutics issued new shares from Dec. 2022 to Dec. 2023 .
The historical data trend for Spero Therapeutics's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spero Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Shares Outstanding (EOP) | Get a 7-Day Free Trial |
![]() |
19.19 | 29.26 | 32.39 | 52.46 | 53.00 |
Spero Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Shares Outstanding (EOP) | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
53.00 | 53.00 | 53.87 | 54.01 | 54.31 |
For the Biotechnology subindustry, Spero Therapeutics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Spero Therapeutics's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Spero Therapeutics's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
Spero Therapeutics (NAS:SPRO) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Thank you for viewing the detailed overview of Spero Therapeutics's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.
Timothy Keutzer | officer: Chief Development Officer | C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
Ankit Mahadevia | director, officer: See Remarks | C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVE., 14TH FLOOR, CAMBRIDGE MA 02139 |
Sath Shukla | officer: Chief Financial Officer | C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129 |
Kamal Hamed | officer: Chief Medical Officer | 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
Tamara L Joseph | officer: Chief Legal Officer | 32 GARRISON STREET, APT 50-103, BOSTON MA 02116 |
Aquilo Capital Management, Llc | 10 percent owner | ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, SAN FRANCISCO CA 94129 |
Kathleen Tregoning | director | C/O CEREVEL THERAPEUTICS HOLDINGS, INC., 131 DARTMOUTH STREET SUITE 502, BOSTON MA 02116 |
Cristina Larkin | officer: Chief Operating Officer | C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
Aquilo Capital, L.p. | 10 percent owner | ONE LETTERMAN DRIVE, SUITE D4900, BUILDING D, THE PRESIDIO, SAN FRANCISCO CA 94129 |
Scott Thomas Jackson | director | 303B COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Stephen J. Dipalma | officer: Interim CFO | C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
Cynthia Smith | director | 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019 |
Pottage John C Jr | director | ACHILLION PHARMACEUTICALS, 300 GEORGE STREET, NEW HAVEN CT 06511 |
Plc Glaxosmithkline | 10 percent owner | 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS |
Joel Sendek | officer: Chief Financial Officer | C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE MA 02139 |
From GuruFocus
By GuruFocus Research • 03-14-2024
By GuruFocus Research • 02-09-2024
By GuruFocus News • 11-13-2024
By Marketwired • 10-16-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By Marketwired • 11-14-2024
By Marketwired • 08-05-2024
By GuruFocus Research • 08-06-2024
By Marketwired • 05-15-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.